Last reviewed · How we verify
Delayed combination therapy
At a glance
| Generic name | Delayed combination therapy |
|---|---|
| Also known as | Cardura® is a registered trademark of Pfizer Inc, Proscar® is a registered trademark of Merck, Hytrin® is a registered trademark of Abbott Laboratories, Uroxatral® is a registered trademark of Sanofi-Aventis, Avodart® is a registered trademark of GlaxoSmithKline |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer (PHASE3)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- Early vs Delayed Intravesical Blad-Care During BCG Therapy (NA)
- Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
- A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy (PHASE3)
- New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Delayed combination therapy CI brief — competitive landscape report
- Delayed combination therapy updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI